Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Grannus Therapeutics LLC
Profile last edited on: 5/3/22      CAGE: 8J1H2      UEI: CKYDPT5R18Z8

Business Identifier: Small molecule inhibitors for specific isoforms of HSP90
Year Founded
2019
First Award
2020
Latest Award
2021
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

7210 North Pennsylvania Street
Indianapolis, IN 46240
   (317) 414-6205
   N/A
   N/A
Location: Single
Congr. District: 05
County: St. Joseph

Public Profile

Spun out of the University of Notre Dame, Grannus Therapeutics LLC personnel organize around development of new anti-cancer agents. A primary focus is on developing novel Hsp90 inhibitors.

Extent of SBIR involvement

User Avatar
Phase I Awards
2
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$579,757
Phase II Dollars
$0
Total Awarded
$579,757

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2021 1 NIH $346,562
Project Title: New Treatments for Glaucoma
2020 1 NIH $233,195
Project Title: Development of HSP90 Beta-Selective Inhibitors as Safer Anti-Cancer Agents

Key People / Management

  John Foglesong -- Co-Founder, President, and CEO

  Sanket Mishra -- Co-Founder

Company News

There are no news available.